Basel Medical Group Ltd (BMGL) company profile
Close on Nov 17, 2026Market cap $513.40KP/E –Yield –
About Basel Medical
Services-Offices & Clinics of Doctors of Medicine, SIC 8011
Basel Medical Group Ltd is a healthcare provider that specializes in orthopedic treatments and related medical services. The company focuses on the diagnosis, correction, prevention, and treatment of disorders affecting the musculoskeletal system, including bones, joints, muscles, ligaments, and tendons. Its operations encompass specialized orthopedic and sports clinics, physiotherapy services, and general medical care delivered through specialized practitioners, external medical professionals, and locum doctors. The organization primarily serves patients requiring orthopedic care, sports injury treatments, physiotherapy, and routine medical consultations.
The group operates medical clinics and facilities across Singapore, including locations in Orchard, Farrer Park, Novena, Suntec, Macpherson, Toa Payoh, Beach Road, Margaret Drive, and Tampines. While incorporated in the British Virgin Islands, Basel Medical Group Ltd maintains its principal executive offices and headquarters at Gleneagles Medical Centre in Singapore.
Summary of the business section of Basel Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Basel Medical Group Ltd
- Headquarters
- Singapore, U0
- Address
- 600 North Bridge Road, #12-02/03, Parkview Square 188778
- Phone
- (656) 291-9188
- Website
- baselmedical.com
- Employees
- 81, Jun 30, 2026
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- Incorporated in
- D8
- Fiscal year ends
- June 30
- Auditor
- NLA DFK Assurance PAC, Singapore
Stock & identifiers
- Ticker
- BMGL
- Exchange
- Nasdaq
- IPO date
- Feb 25, 2025
- Shares outstanding
- 2M, Jun 30, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-12 reverse, Jun 22, 2026
- SEC CIK
- 2004489
- FIGI
- BBG01PR70N34
- Share class FIGI
- BBG01PR70NY0
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Boon Chye Tan | Chief Commercial Officer, Director | 10,205,229 |
| Alton Chun How Neo | Interim CFO | – |
| Jianing JN Lu | Chief Financial Officer | – |
| Darren Yen Feng Chhoa | Chief Executive Officer | – |
| Xinwen Yang | Director | – |
| Frederick Shieh Ming Hong | Director | – |
| Kwek Yoon Soong | Director | – |
| Keng Leong Fung | Director | 10,205,229 |
| Tony Chen | Director | – |
| Paul D. Freudenthaler | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 25, 2025
- Exchange
- Nasdaq
- First trading day
- Feb 25, 2025
- First-day close
- $4.44
- Lock-up ends (est.)
- Aug 24, 2025
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We had 81 full-time employees as of June 30, 2025, and 74 full-time employees as of June 30, 2026.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 27, 2025 | Late filing | Notification of late filing |
| Feb 25, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 14, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?